| P50 | author | Grant D Trobridge | Q117811734 |
| | Peter J. Felsburg | Q117811741 |
| | Christopher Burtner | Q117811742 |
| | Brian Beard | Q61793675 |
| | Jennifer E Adair | Q63955664 |
| | Hans-Peter Kiem | Q88408730 |
| | Andrew M Scharenberg | Q89137190 |
| | Troy R Torgerson | Q96130732 |
| P2093 | author name string | David J Rawlings | |
| | Douglas R Kennedy | |
| | Martin E Wohlfahrt | |
| P2860 | cites work | Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia | Q24618997 |
| | Correction of canine X-linked severe combined immunodeficiency by in vivo retroviral gene therapy | Q24685725 |
| | Proliferation-linked apoptosis of adoptively transferred T cells after IL-15 administration in macaques | Q27314843 |
| | Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease | Q28143064 |
| | LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 | Q28210584 |
| | Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy | Q28215190 |
| | Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution | Q28251498 |
| | Development of population-based newborn screening for severe combined immunodeficiency | Q28306288 |
| | Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15 | Q28610814 |
| | Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs | Q30476504 |
| | Selection of the T cell repertoire. | Q33652536 |
| | 20 years of gene therapy for SCID. | Q34116369 |
| | Primary immunodeficiency diseases: an experimental model for molecular medicine | Q34284845 |
| | The primary immunodeficiencies | Q34300415 |
| | Foamy virus vector integration sites in normal human cells | Q34334976 |
| | Stem cell selection in vivo using foamy vectors cures canine pyruvate kinase deficiency | Q34428276 |
| | Treatment of canine leukocyte adhesion deficiency by foamy virus vectors expressing CD18 from a PGK promoter | Q34819562 |
| | Foamy combinatorial anti-HIV vectors with MGMTP140K potently inhibit HIV-1 and SHIV replication and mediate selection in vivo | Q35182775 |
| | Gene therapy progress and prospects: gene therapy for severe combined immunodeficiency | Q35562854 |
| | Foamy-virus-mediated gene transfer to canine repopulating cells | Q35615750 |
| | Cell Membrane-associated heparan sulfate is a receptor for prototype foamy virus in human, monkey, and rodent cells | Q36014113 |
| | Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors | Q36362910 |
| | Extended survival of glioblastoma patients after chemoprotective HSC gene therapy | Q36834118 |
| | Cell cycle requirements for transduction by foamy virus vectors compared to those of oncovirus and lentivirus vectors | Q36954062 |
| | Somatic mosaicism in primary immune deficiencies | Q37315154 |
| | γδ T-cells: cross-talk between innate and adaptive immunity | Q37871905 |
| | Therapy and prevention of cryptosporidiosis in animals | Q38004333 |
| | Gene therapy of primary T cell immunodeficiencies | Q38098818 |
| | Stable marking and transgene expression without progression to monoclonality in canine long-term hematopoietic repopulating cells transduced with lentiviral vectors | Q40386929 |
| | In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs | Q41524708 |
| | T cell repertoire development in XSCID dogs following nonconditioned allogeneic bone marrow transplantation | Q41950077 |
| | Biochemical characterization of a unique canine myeloid antigen | Q44604716 |
| | Nitazoxanide for severe cryptosporidial diarrhea in human immunodeficiency virus infected children | Q45388905 |
| | Unique integration profiles in a canine model of long-term repopulating cells transduced with gammaretrovirus, lentivirus, or foamy virus | Q45403720 |
| | Morphology of experimental malignant hemangioendothelioma | Q45636790 |
| | A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency | Q45857796 |
| | Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector | Q45880148 |
| | Intrinsic defects of B cell function in X-linked severe combined immunodeficiency | Q57914829 |
| | Atypical X-Linked Severe Combined Immunodeficiency Due to Possible Spontaneous Reversion of the Genetic Defect in T Cells | Q63859659 |
| | European experience of bone-marrow transplantation for severe combined immunodeficiency | Q68158333 |
| | Foamy virus vectors | Q70792195 |
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vector-borne disease | Q2083837 |
| P304 | page(s) | 3578-3584 | |
| P577 | publication date | 2014-03-18 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Intravenous injection of a foamy virus vector to correct canine SCID-X1 | |
| P478 | volume | 123 | |